Radojković, Milica

Link to this page

Authority KeyName Variants
0112f013-b64e-47c8-a0f0-dddd1aca2e35
  • Radojković, Milica (7)
Projects

Author's Bibliography

Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype

Denčić-Fekete, Marija; Terzić, Tatjana; Jaković, Ljubomir; Đurašinović, Vladislava; Karan-Đurašević, Teodora ; Radojković, Milica; Pavlović, Sonja; Bogdanović, Andrija

(2023)

TY  - JOUR
AU  - Denčić-Fekete, Marija
AU  - Terzić, Tatjana
AU  - Jaković, Ljubomir
AU  - Đurašinović, Vladislava
AU  - Karan-Đurašević, Teodora 
AU  - Radojković, Milica
AU  - Pavlović, Sonja
AU  - Bogdanović, Andrija
PY  - 2023
UR  - https://doiserbia.nb.rs/Article.aspx?ID=0042-84502200060D
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2191
AB  - Introduction. The presence of aneuploidy in patients diagnosed with chronic lymphocytic leukemia (CLL), except trisomy 12, is considered quite uncommon. Hyperdiploidy or near-tetraploidy (occurring in 1–3% of all CLL patients) usually confer a poor prognosis. Case report. We report a patient in a progressive phase of CLL with near–triploid karyotype. The prognosis of the disease was more precisely determined by applying the cytogenetic analysis of the karyotype and was complemented with molecular methods and pathohistological examination. The complex karyotype was accompanied by the TP53, C-MYC, and IGH gene disruptions, the most probable cause of rapid evolution into Richter’s syndrome. Conclusion. The use of comprehensive contemporary diagnostic techniques is highly recommended in patients who are in the progressive phase of CLL, primarily for the adequate choice of management strategy. The presented case confirms that aneuploidy in CLL patients indicates poor prognosis, which is in accordance with previous publications reporting on cases of CLL patients with aneuploidy.
AB  - Uvod. Prisustvo aneuploidije kod bolesnika sa dijagnozom hronične limfocitne leukemije (HLL), sa izuzetkom trizomije 12, smatra se retkom pojavom. Pojava hiperdiploidnog ili kariotipa blizu tetraploidnog broja hromozoma (koji se javlja kod 1–3% svih bolesnika sa HLL) smatra se lošim prognostičkim parametrom. Prikaz bolesnika. Prikazan je bolesnik u uznapredovaloj fazi HLL sa kariotipom blizu triploidnog broja hromozoma. Prognoza bolesti je preciznije određena citogenetičkom analizom kariotipa bolesnika, i dopunjena molekularnim metodama i patohistološkom analizom. Otkriveno je prisustvo kompleksnog kariotipa udruženog sa poremećajima u genima TP53, C-MYC i IGH, što je najverovatnije bio uzrok brze progresije u Rihterov sindrom. Zaključak. Primena savremenih dijagnostičkih metoda veoma je značajna kod bolesnika u uznapredovaloj fazi HLL, prvenstveno zbog adekvatnog terapijskog pristupa. Prikazani slučaj ukazuje da je prisustvo aneuploidije kod bolesnika sa HLL loš prognostički znak, što je u saglasnosti sa prethodno publikovanim prikazima bolesnika sa HLL i sa aneuploidijom u kariotipu.
T2  - Vojnosanitetski pregled
T1  - Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype
T1  - Brza progresija hronične limfocitne leukemije u Rihterov sindrom kod bolesnika sa kariotipom blizu triploidnog broja hromozom
EP  - 457
IS  - 5
SP  - 454
VL  - 80
DO  - 10.2298/VSP211111060D
ER  - 
@article{
author = "Denčić-Fekete, Marija and Terzić, Tatjana and Jaković, Ljubomir and Đurašinović, Vladislava and Karan-Đurašević, Teodora  and Radojković, Milica and Pavlović, Sonja and Bogdanović, Andrija",
year = "2023",
abstract = "Introduction. The presence of aneuploidy in patients diagnosed with chronic lymphocytic leukemia (CLL), except trisomy 12, is considered quite uncommon. Hyperdiploidy or near-tetraploidy (occurring in 1–3% of all CLL patients) usually confer a poor prognosis. Case report. We report a patient in a progressive phase of CLL with near–triploid karyotype. The prognosis of the disease was more precisely determined by applying the cytogenetic analysis of the karyotype and was complemented with molecular methods and pathohistological examination. The complex karyotype was accompanied by the TP53, C-MYC, and IGH gene disruptions, the most probable cause of rapid evolution into Richter’s syndrome. Conclusion. The use of comprehensive contemporary diagnostic techniques is highly recommended in patients who are in the progressive phase of CLL, primarily for the adequate choice of management strategy. The presented case confirms that aneuploidy in CLL patients indicates poor prognosis, which is in accordance with previous publications reporting on cases of CLL patients with aneuploidy., Uvod. Prisustvo aneuploidije kod bolesnika sa dijagnozom hronične limfocitne leukemije (HLL), sa izuzetkom trizomije 12, smatra se retkom pojavom. Pojava hiperdiploidnog ili kariotipa blizu tetraploidnog broja hromozoma (koji se javlja kod 1–3% svih bolesnika sa HLL) smatra se lošim prognostičkim parametrom. Prikaz bolesnika. Prikazan je bolesnik u uznapredovaloj fazi HLL sa kariotipom blizu triploidnog broja hromozoma. Prognoza bolesti je preciznije određena citogenetičkom analizom kariotipa bolesnika, i dopunjena molekularnim metodama i patohistološkom analizom. Otkriveno je prisustvo kompleksnog kariotipa udruženog sa poremećajima u genima TP53, C-MYC i IGH, što je najverovatnije bio uzrok brze progresije u Rihterov sindrom. Zaključak. Primena savremenih dijagnostičkih metoda veoma je značajna kod bolesnika u uznapredovaloj fazi HLL, prvenstveno zbog adekvatnog terapijskog pristupa. Prikazani slučaj ukazuje da je prisustvo aneuploidije kod bolesnika sa HLL loš prognostički znak, što je u saglasnosti sa prethodno publikovanim prikazima bolesnika sa HLL i sa aneuploidijom u kariotipu.",
journal = "Vojnosanitetski pregled",
title = "Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype, Brza progresija hronične limfocitne leukemije u Rihterov sindrom kod bolesnika sa kariotipom blizu triploidnog broja hromozom",
pages = "457-454",
number = "5",
volume = "80",
doi = "10.2298/VSP211111060D"
}
Denčić-Fekete, M., Terzić, T., Jaković, L., Đurašinović, V., Karan-Đurašević, T., Radojković, M., Pavlović, S.,& Bogdanović, A.. (2023). Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype. in Vojnosanitetski pregled, 80(5), 454-457.
https://doi.org/10.2298/VSP211111060D
Denčić-Fekete M, Terzić T, Jaković L, Đurašinović V, Karan-Đurašević T, Radojković M, Pavlović S, Bogdanović A. Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype. in Vojnosanitetski pregled. 2023;80(5):454-457.
doi:10.2298/VSP211111060D .
Denčić-Fekete, Marija, Terzić, Tatjana, Jaković, Ljubomir, Đurašinović, Vladislava, Karan-Đurašević, Teodora , Radojković, Milica, Pavlović, Sonja, Bogdanović, Andrija, "Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype" in Vojnosanitetski pregled, 80, no. 5 (2023):454-457,
https://doi.org/10.2298/VSP211111060D . .

Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation

Čolović, Nataša; Đorđević, Vesna; Radojković, Milica; Karan-Đurašević, Teodora; Tošić, Nataša

(2023)

TY  - JOUR
AU  - Čolović, Nataša
AU  - Đorđević, Vesna
AU  - Radojković, Milica
AU  - Karan-Đurašević, Teodora
AU  - Tošić, Nataša
PY  - 2023
UR  - https://doiserbia.nb.rs/Article.aspx?ID=0370-81792300100C
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2292
AB  - Introduction. Chromosomal numerical aberrations are very common in hematological malignancies, but near-tetraploidy (80-104 chromosomes) is rare in myeloid lineage malignancies, with only a few cases reported in myelodysplastic syndrome (MDS). Due to a small number of cases with this rare cytogenetic abnormality, clinicopathological significance of near-tetraploidy in MDS is still unknown. In this case report we present a case of de novo MDS patient with near-tetraploidy in association with TP53 mutation, and we aimed to elucidate the prognostic significance of this rare genetic feature. Case Outline. In August of 2018 a 71-year-old male presented with severe anemia, thrombocytopenia, and leucopenia and enlarged spleen. Laboratory data were as follows: hemoglobin (Hb) 93 g/L, white blood cells (WBC) 2.8×109/L and platelets 23x109/L. The bone marrow aspirate was hypercellular, megakaryocytes were not found, granulocytic cells were 15% with signs of dysplasia, with 16% of blast cells without Auer rods. The finding was in correlation with diagnosis of MDS, type RAEB2 which was also confirmed by immunophenotyping. Cytogenetic finding was near-tetraploidy (48,XY+mar[10]/92,XXYY[10]), and TP53 mutational analysis showed the presence of mutation in exon 8 (p.D281A; c.842 A>C). The patient received from time-to-time packed red blood cells and platelets, and died four months after initial diagnosis. Conclusion. Near-tetraploidy associated with TP53 mutation has been described only in few MDS cases. Results of these reports including ours suggest that the association of TP53 mutation and near-tetra polyploidy is a poor prognostic factor.
AB  - Нумеричке аберације хромозома су веома честе код хематолошких малигнитета, али су приближне тетраплои- дије (80–104 хромозома) ретке у малигнитетима мијелоидне лозе, са само неколико случајева пријављених у мијелоди- спластичком синдрому (МДС). Због малог броја случајева са овом ретком цитогенетском абнормалношћу, клиничко- -патолошки значај приближне тетраплоидије у МДС-у је још увек непознат. Овим приказом de novo болесника са МДС-ом, са приближном тетраплоидијом и мутацијом у гену TP53, циљ нам је био да расветлимо прогностички значај ове рет- ке генетске карактеристикe. Приказ болесника Приказан је 71-годишњи болесник који је у августу 2018. године развио симптоме тешке анемије, тромбоцитопеније, леукопеније и увећане слезине. Лабо- раторијске анализе су показале следеће: хемоглобин 93 g/L, леукоцити 2,8 × 109 /L и тромбоцити 23 × 109 /L. Аспират коштане сржи је био хиперћелијски, мегакариоцити нису на- ђени, 15% гранулоцитa је било са знацима дисплазије, 16% бластa без Ауерових штапића. Налаз је одговарао дијагнози МДС-а, типа рефракторне анемије са вишком бласта 2, што је потврђено и имунолошком фенотипизацијом. Цитогенет- ском анализом утврђено је присуство приближне тетрапло- идије (48,XY+mar10/92,XXYY[10]), а анализа мутација у гену TP53 показала је присуство мутације у егзону 8 (p.D281A; c.842 A > C). Болесник је по потреби примао трансфузију еритроцита и тромбоците, а умро је четири месеца након почетне дијагнозе. Закључак Присуство приближне тетраплоидије удружене са мутацијама у гену TP53 описано је само у неколико слу- чајева МДС-а. Резултати ових случајева, као и наши резул- тати, указују на то да приближна тетраплоидија повезана са присуством мутација у гену TP53 представља фактор лоше прогнозе.
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
T1  - Мијелодиспластични синдром са приближном тетраплоидијом удруженом са мутацијом гена TP53 – редак случај
EP  - n/a
IS  - n/a
SP  - n/a
DO  - 10.2298/SARH230728100C
ER  - 
@article{
author = "Čolović, Nataša and Đorđević, Vesna and Radojković, Milica and Karan-Đurašević, Teodora and Tošić, Nataša",
year = "2023",
abstract = "Introduction. Chromosomal numerical aberrations are very common in hematological malignancies, but near-tetraploidy (80-104 chromosomes) is rare in myeloid lineage malignancies, with only a few cases reported in myelodysplastic syndrome (MDS). Due to a small number of cases with this rare cytogenetic abnormality, clinicopathological significance of near-tetraploidy in MDS is still unknown. In this case report we present a case of de novo MDS patient with near-tetraploidy in association with TP53 mutation, and we aimed to elucidate the prognostic significance of this rare genetic feature. Case Outline. In August of 2018 a 71-year-old male presented with severe anemia, thrombocytopenia, and leucopenia and enlarged spleen. Laboratory data were as follows: hemoglobin (Hb) 93 g/L, white blood cells (WBC) 2.8×109/L and platelets 23x109/L. The bone marrow aspirate was hypercellular, megakaryocytes were not found, granulocytic cells were 15% with signs of dysplasia, with 16% of blast cells without Auer rods. The finding was in correlation with diagnosis of MDS, type RAEB2 which was also confirmed by immunophenotyping. Cytogenetic finding was near-tetraploidy (48,XY+mar[10]/92,XXYY[10]), and TP53 mutational analysis showed the presence of mutation in exon 8 (p.D281A; c.842 A>C). The patient received from time-to-time packed red blood cells and platelets, and died four months after initial diagnosis. Conclusion. Near-tetraploidy associated with TP53 mutation has been described only in few MDS cases. Results of these reports including ours suggest that the association of TP53 mutation and near-tetra polyploidy is a poor prognostic factor., Нумеричке аберације хромозома су веома честе код хематолошких малигнитета, али су приближне тетраплои- дије (80–104 хромозома) ретке у малигнитетима мијелоидне лозе, са само неколико случајева пријављених у мијелоди- спластичком синдрому (МДС). Због малог броја случајева са овом ретком цитогенетском абнормалношћу, клиничко- -патолошки значај приближне тетраплоидије у МДС-у је још увек непознат. Овим приказом de novo болесника са МДС-ом, са приближном тетраплоидијом и мутацијом у гену TP53, циљ нам је био да расветлимо прогностички значај ове рет- ке генетске карактеристикe. Приказ болесника Приказан је 71-годишњи болесник који је у августу 2018. године развио симптоме тешке анемије, тромбоцитопеније, леукопеније и увећане слезине. Лабо- раторијске анализе су показале следеће: хемоглобин 93 g/L, леукоцити 2,8 × 109 /L и тромбоцити 23 × 109 /L. Аспират коштане сржи је био хиперћелијски, мегакариоцити нису на- ђени, 15% гранулоцитa је било са знацима дисплазије, 16% бластa без Ауерових штапића. Налаз је одговарао дијагнози МДС-а, типа рефракторне анемије са вишком бласта 2, што је потврђено и имунолошком фенотипизацијом. Цитогенет- ском анализом утврђено је присуство приближне тетрапло- идије (48,XY+mar10/92,XXYY[10]), а анализа мутација у гену TP53 показала је присуство мутације у егзону 8 (p.D281A; c.842 A > C). Болесник је по потреби примао трансфузију еритроцита и тромбоците, а умро је четири месеца након почетне дијагнозе. Закључак Присуство приближне тетраплоидије удружене са мутацијама у гену TP53 описано је само у неколико слу- чајева МДС-а. Резултати ових случајева, као и наши резул- тати, указују на то да приближна тетраплоидија повезана са присуством мутација у гену TP53 представља фактор лоше прогнозе.",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation, Мијелодиспластични синдром са приближном тетраплоидијом удруженом са мутацијом гена TP53 – редак случај",
pages = "n/a-n/a",
number = "n/a",
doi = "10.2298/SARH230728100C"
}
Čolović, N., Đorđević, V., Radojković, M., Karan-Đurašević, T.,& Tošić, N.. (2023). Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation. in Srpski arhiv za celokupno lekarstvo(n/a), n/a-n/a.
https://doi.org/10.2298/SARH230728100C
Čolović N, Đorđević V, Radojković M, Karan-Đurašević T, Tošić N. Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation. in Srpski arhiv za celokupno lekarstvo. 2023;(n/a):n/a-n/a.
doi:10.2298/SARH230728100C .
Čolović, Nataša, Đorđević, Vesna, Radojković, Milica, Karan-Đurašević, Teodora, Tošić, Nataša, "Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation" in Srpski arhiv za celokupno lekarstvo, no. n/a (2023):n/a-n/a,
https://doi.org/10.2298/SARH230728100C . .

Varijante gena "VKORC1" i "CYP2C9" kao farmakogenetički faktori u terapiji acenokumarolom kod bolesnika u Srbiji - razmatranje preosetljivosti i rezistencije

Rakićević, Ljiljana; Kovač, Mirjana; Radojković, Dragica; Radojković, Milica

(Srpsko lekarsko društvo, Beograd, 2022)

TY  - JOUR
AU  - Rakićević, Ljiljana
AU  - Kovač, Mirjana
AU  - Radojković, Dragica
AU  - Radojković, Milica
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1587
AB  - Uvod/Cilj Terapija kumarinima predstavlja jedan od najboljih modela za primenu farmakogenetike. Doprinos faktora koji utiču na terapiju kumarinima može značajno da varira između etničkih grupa, što opravdava sprovođenje studija specifičnih za populaciju. Cilj ove studije je bio da se analizira uticaj najvažnijih genetičkih faktora (geni VKORC1 i CYP2C9) koji utiču na terapiju kumarinima kod bolesnika iz Srbije. Metode Sprovedena je retrospektivna studija koja je obuhvatila 207 bolesnika na terapiji acenokumarolom. Genetičke analize su vršene direktnim sekvenciranjem. Analiziran je uticaj na dozu acenokumarola varijanti (VKORC1*2, CYP2C9*2, CYP2C9*3) koje izazivaju preosetljivost i varijanti gena VKORC1 koje izazivaju rezistenciju na kumarine. Višestruka regresiona analiza je korišćena u cilju dizajniranja matematičkog modela za predviđanje individualne doze leka na osnovu kliničko-demografskih i genetičkih podataka. Rezultati Studija je potvrdila značajan uticaj analiziranih genetičkih faktora na održavanje doze acenokumarola. Dizajniran je matematički model za predviđanje individualne doze acenokumarola i njegov nekorigovani R2 je bio 61,8. Prilikom testiranja, naš model je dao R2 vrednost od 42,6 i pokazao bolje predviđanje u poređenju sa modelom koji su dali drugi autori. Kod analiziranih bolesnika pronađeno je devet različitih varijanti u kodirajućem regionu gena VKORC1. Među nosiocima ovih varijanti 78% je bilo potpuno rezistentno, te nije bilo moguće postići terapeutski efekat čak ni sa visokim dozama acenokumarola. Zaključci Populacioni model za predviđanje individualne doze acenokumarola može pokazati prednosti u odnosu na modele koji se koriste na generalizovan način. Takođe, VKORC1 varijante koje izazivaju rezistenciju na kumarin treba uzeti u obzir prilikom planiranja terapije.
AB  - Introduction/Objective Coumarin therapy represents one of the best models for applying pharmacogenetics. The contribution of factors influencing coumarin therapy can vary significantly between ethnic groups, which justifies conducting population-specific studies. The aim of this study was to analyze the influence of the most important genetic factors (VKORC1 and CYP2C9 genes) that affect coumarin therapy in patients from Serbia. Methods A retrospective study involving 207 patients on acenocoumarol therapy was conducted. Genetic analyses were performed by direct sequencing. Influence on acenocoumarol dose of variants (VKORC1, CYP2C9*2, CYP2C9*3) causing hypersensitivity and VKORC1 variants causing resistance to acenocoumarol were analyzed. Multiple regression analysis was used to design a mathematical model for predicting individual drug dosage based on clinical-demographic and genetic data. Results The study confirmed significant influence of the analyzed genetic factors on acenocoumarol maintenance dose. We designed mathematical model for predicting individual acenocoumarol dose and its unadjusted R2 was 61.8. In the testing cohort, our model gave R2 value of 42.6 and showed better prediction in comparison with model given by other authors. In the analyzed patients, nine different variants in the VKORC1 coding region were found. Among carriers of these variants 78% were completely resistant, and it was not possible to achieve therapeutic effect even with high doses of acenocoumarol. Conclusions Population-specific model for prediction individual dose of acenocoumarol, may show advantages over protocols that are used in a generalized manner. Also, VKORC1 variants which cause coumarin resistance should be considered when planning therapy.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Varijante gena "VKORC1" i "CYP2C9" kao farmakogenetički faktori u terapiji acenokumarolom kod bolesnika u Srbiji - razmatranje preosetljivosti i rezistencije
T1  - The 'VKORC1' and 'CYP2C9' gene variants as pharmacogenetic factors in acenocoumarol therapy in Serbian patients: Consideration of hypersensitivity and resistance
EP  - 162
IS  - 3-4
SP  - 156
VL  - 150
DO  - 10.2298/SARH211118013R
ER  - 
@article{
author = "Rakićević, Ljiljana and Kovač, Mirjana and Radojković, Dragica and Radojković, Milica",
year = "2022",
abstract = "Uvod/Cilj Terapija kumarinima predstavlja jedan od najboljih modela za primenu farmakogenetike. Doprinos faktora koji utiču na terapiju kumarinima može značajno da varira između etničkih grupa, što opravdava sprovođenje studija specifičnih za populaciju. Cilj ove studije je bio da se analizira uticaj najvažnijih genetičkih faktora (geni VKORC1 i CYP2C9) koji utiču na terapiju kumarinima kod bolesnika iz Srbije. Metode Sprovedena je retrospektivna studija koja je obuhvatila 207 bolesnika na terapiji acenokumarolom. Genetičke analize su vršene direktnim sekvenciranjem. Analiziran je uticaj na dozu acenokumarola varijanti (VKORC1*2, CYP2C9*2, CYP2C9*3) koje izazivaju preosetljivost i varijanti gena VKORC1 koje izazivaju rezistenciju na kumarine. Višestruka regresiona analiza je korišćena u cilju dizajniranja matematičkog modela za predviđanje individualne doze leka na osnovu kliničko-demografskih i genetičkih podataka. Rezultati Studija je potvrdila značajan uticaj analiziranih genetičkih faktora na održavanje doze acenokumarola. Dizajniran je matematički model za predviđanje individualne doze acenokumarola i njegov nekorigovani R2 je bio 61,8. Prilikom testiranja, naš model je dao R2 vrednost od 42,6 i pokazao bolje predviđanje u poređenju sa modelom koji su dali drugi autori. Kod analiziranih bolesnika pronađeno je devet različitih varijanti u kodirajućem regionu gena VKORC1. Među nosiocima ovih varijanti 78% je bilo potpuno rezistentno, te nije bilo moguće postići terapeutski efekat čak ni sa visokim dozama acenokumarola. Zaključci Populacioni model za predviđanje individualne doze acenokumarola može pokazati prednosti u odnosu na modele koji se koriste na generalizovan način. Takođe, VKORC1 varijante koje izazivaju rezistenciju na kumarin treba uzeti u obzir prilikom planiranja terapije., Introduction/Objective Coumarin therapy represents one of the best models for applying pharmacogenetics. The contribution of factors influencing coumarin therapy can vary significantly between ethnic groups, which justifies conducting population-specific studies. The aim of this study was to analyze the influence of the most important genetic factors (VKORC1 and CYP2C9 genes) that affect coumarin therapy in patients from Serbia. Methods A retrospective study involving 207 patients on acenocoumarol therapy was conducted. Genetic analyses were performed by direct sequencing. Influence on acenocoumarol dose of variants (VKORC1, CYP2C9*2, CYP2C9*3) causing hypersensitivity and VKORC1 variants causing resistance to acenocoumarol were analyzed. Multiple regression analysis was used to design a mathematical model for predicting individual drug dosage based on clinical-demographic and genetic data. Results The study confirmed significant influence of the analyzed genetic factors on acenocoumarol maintenance dose. We designed mathematical model for predicting individual acenocoumarol dose and its unadjusted R2 was 61.8. In the testing cohort, our model gave R2 value of 42.6 and showed better prediction in comparison with model given by other authors. In the analyzed patients, nine different variants in the VKORC1 coding region were found. Among carriers of these variants 78% were completely resistant, and it was not possible to achieve therapeutic effect even with high doses of acenocoumarol. Conclusions Population-specific model for prediction individual dose of acenocoumarol, may show advantages over protocols that are used in a generalized manner. Also, VKORC1 variants which cause coumarin resistance should be considered when planning therapy.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Varijante gena "VKORC1" i "CYP2C9" kao farmakogenetički faktori u terapiji acenokumarolom kod bolesnika u Srbiji - razmatranje preosetljivosti i rezistencije, The 'VKORC1' and 'CYP2C9' gene variants as pharmacogenetic factors in acenocoumarol therapy in Serbian patients: Consideration of hypersensitivity and resistance",
pages = "162-156",
number = "3-4",
volume = "150",
doi = "10.2298/SARH211118013R"
}
Rakićević, L., Kovač, M., Radojković, D.,& Radojković, M.. (2022). Varijante gena "VKORC1" i "CYP2C9" kao farmakogenetički faktori u terapiji acenokumarolom kod bolesnika u Srbiji - razmatranje preosetljivosti i rezistencije. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 150(3-4), 156-162.
https://doi.org/10.2298/SARH211118013R
Rakićević L, Kovač M, Radojković D, Radojković M. Varijante gena "VKORC1" i "CYP2C9" kao farmakogenetički faktori u terapiji acenokumarolom kod bolesnika u Srbiji - razmatranje preosetljivosti i rezistencije. in Srpski arhiv za celokupno lekarstvo. 2022;150(3-4):156-162.
doi:10.2298/SARH211118013R .
Rakićević, Ljiljana, Kovač, Mirjana, Radojković, Dragica, Radojković, Milica, "Varijante gena "VKORC1" i "CYP2C9" kao farmakogenetički faktori u terapiji acenokumarolom kod bolesnika u Srbiji - razmatranje preosetljivosti i rezistencije" in Srpski arhiv za celokupno lekarstvo, 150, no. 3-4 (2022):156-162,
https://doi.org/10.2298/SARH211118013R . .
1

Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma

Bila, Jelena; Sretenović, Aleksandra; Jelicić, Jelena; Tošić, Nataša; Marjanović, Irena; Fekete, Marija Dencic; Antić, Darko; Todorovic-Balint, Milena; Marković, Olivera; Milojević, Zoran; Radojković, Milica; Trajković, Goran; Purić, Mila; Pavlović, Sonja; Mihaljević, Biljana

(CIG Media Group, Lp, Dallas, 2016)

TY  - JOUR
AU  - Bila, Jelena
AU  - Sretenović, Aleksandra
AU  - Jelicić, Jelena
AU  - Tošić, Nataša
AU  - Marjanović, Irena
AU  - Fekete, Marija Dencic
AU  - Antić, Darko
AU  - Todorovic-Balint, Milena
AU  - Marković, Olivera
AU  - Milojević, Zoran
AU  - Radojković, Milica
AU  - Trajković, Goran
AU  - Purić, Mila
AU  - Pavlović, Sonja
AU  - Mihaljević, Biljana
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/962
AB  - Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.
PB  - CIG Media Group, Lp, Dallas
T2  - Clinical Lymphoma Myeloma & Leukemia
T1  - Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
EP  - 615
IS  - 11
SP  - 610
VL  - 16
DO  - 10.1016/j.clml.2016.08.007
ER  - 
@article{
author = "Bila, Jelena and Sretenović, Aleksandra and Jelicić, Jelena and Tošić, Nataša and Marjanović, Irena and Fekete, Marija Dencic and Antić, Darko and Todorovic-Balint, Milena and Marković, Olivera and Milojević, Zoran and Radojković, Milica and Trajković, Goran and Purić, Mila and Pavlović, Sonja and Mihaljević, Biljana",
year = "2016",
abstract = "Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.",
publisher = "CIG Media Group, Lp, Dallas",
journal = "Clinical Lymphoma Myeloma & Leukemia",
title = "Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma",
pages = "615-610",
number = "11",
volume = "16",
doi = "10.1016/j.clml.2016.08.007"
}
Bila, J., Sretenović, A., Jelicić, J., Tošić, N., Marjanović, I., Fekete, M. D., Antić, D., Todorovic-Balint, M., Marković, O., Milojević, Z., Radojković, M., Trajković, G., Purić, M., Pavlović, S.,& Mihaljević, B.. (2016). Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. in Clinical Lymphoma Myeloma & Leukemia
CIG Media Group, Lp, Dallas., 16(11), 610-615.
https://doi.org/10.1016/j.clml.2016.08.007
Bila J, Sretenović A, Jelicić J, Tošić N, Marjanović I, Fekete MD, Antić D, Todorovic-Balint M, Marković O, Milojević Z, Radojković M, Trajković G, Purić M, Pavlović S, Mihaljević B. Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. in Clinical Lymphoma Myeloma & Leukemia. 2016;16(11):610-615.
doi:10.1016/j.clml.2016.08.007 .
Bila, Jelena, Sretenović, Aleksandra, Jelicić, Jelena, Tošić, Nataša, Marjanović, Irena, Fekete, Marija Dencic, Antić, Darko, Todorovic-Balint, Milena, Marković, Olivera, Milojević, Zoran, Radojković, Milica, Trajković, Goran, Purić, Mila, Pavlović, Sonja, Mihaljević, Biljana, "Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma" in Clinical Lymphoma Myeloma & Leukemia, 16, no. 11 (2016):610-615,
https://doi.org/10.1016/j.clml.2016.08.007 . .
1
13
4
11

JAK2V617F mutacija kod bolesnika sa B ćelijskom hroničnom limfocitnom leukemijom i prefibrotičkom primarnom mijelofibrozom

Ristić, Slobodan; Radojković, Milica; Kostić, Tatjana; Spasovski, Vesna; Pavlović, Sonja; Čemerikić-Martinović, Vesna

(Srpsko lekarsko društvo, Beograd, 2015)

TY  - JOUR
AU  - Ristić, Slobodan
AU  - Radojković, Milica
AU  - Kostić, Tatjana
AU  - Spasovski, Vesna
AU  - Pavlović, Sonja
AU  - Čemerikić-Martinović, Vesna
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/800
AB  - Uvod Sekundarni maligniteti, naročito solidni tumori, česti su kod bolesnika s hroničnom limfocitnom leukemijom (HLL), ali retko se sreće udruženost mijeloproliferativnih neoplazmi i HLL. Prikaz bolesnika Prikazujemo muškarca starog 67 godina sa B ćelijskom HLL kod koga se nakon devet godina razvila primarna mijelofibroza (PMF). Bolesnik je lečen alkilišućim agensima i analozima purina, što može biti predisponirajući faktor za razvoj mijeloproliferativnog oboljenja. JAK2V617F mutacija nije otkrivena prilikom postavljanja dijagnoze HLL, ali je utvrđena posle devet godina, kada se razvila PMF, što ukazuje na to da su B ćelijska HLL i PMF neoplazme koje potiču od različitih ćelijskih klonova. Zaključak Patogenetski mehanizmi udruženosti mijeloproliferativne i limfoproliferativne neoplazme kod bolesnika nisu razjašnjeni. Potrebna su dalja istraživanja radi utvrđivanja da li ove maligne bolesti potiču od dva različita ćelijska klona ili nastaju od iste pluripotentne matične ćelije hematopoeze.
AB  - Introduction Secondary malignancies, particularly solid tumors, are common in patients with chronic lymphocytic leukemia (CLL), but association of myeloproliferative neoplasms and chronic lymphocytic leukemia in the same patient is very rare. Case Outline We report of a 67-year-old man with B-cell chronic lymphoid leukemia (B-CLL) who developed primary myelofibrosis (PMF) nine years after initial diagnosis. Patient received alkylation agents and purine analogue, which can be a predisposing factor for the development of myeloproliferative neoplasms. JAK2V617F mutation was not present initially at the time of CLL diagnosis, but was found after nine years when PMF occurred, which indicates that B-CLL and PMF represent two separate clonal origin neoplasms. Conclusion Pathogenic mechanisms for the development of myeloproliferative and lymphoproliferative neoplasms in the same patient are unknown. Further research is needed to determine whether these malignancies originate from two different cell clones or arise from the same pluripotent hematopoietic stem cell.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - JAK2V617F mutacija kod bolesnika sa B ćelijskom hroničnom limfocitnom leukemijom i prefibrotičkom primarnom mijelofibrozom
T1  - JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis
EP  - 743
IS  - 11-12
SP  - 739
VL  - 143
DO  - 10.2298/SARH1512739R
ER  - 
@article{
author = "Ristić, Slobodan and Radojković, Milica and Kostić, Tatjana and Spasovski, Vesna and Pavlović, Sonja and Čemerikić-Martinović, Vesna",
year = "2015",
abstract = "Uvod Sekundarni maligniteti, naročito solidni tumori, česti su kod bolesnika s hroničnom limfocitnom leukemijom (HLL), ali retko se sreće udruženost mijeloproliferativnih neoplazmi i HLL. Prikaz bolesnika Prikazujemo muškarca starog 67 godina sa B ćelijskom HLL kod koga se nakon devet godina razvila primarna mijelofibroza (PMF). Bolesnik je lečen alkilišućim agensima i analozima purina, što može biti predisponirajući faktor za razvoj mijeloproliferativnog oboljenja. JAK2V617F mutacija nije otkrivena prilikom postavljanja dijagnoze HLL, ali je utvrđena posle devet godina, kada se razvila PMF, što ukazuje na to da su B ćelijska HLL i PMF neoplazme koje potiču od različitih ćelijskih klonova. Zaključak Patogenetski mehanizmi udruženosti mijeloproliferativne i limfoproliferativne neoplazme kod bolesnika nisu razjašnjeni. Potrebna su dalja istraživanja radi utvrđivanja da li ove maligne bolesti potiču od dva različita ćelijska klona ili nastaju od iste pluripotentne matične ćelije hematopoeze., Introduction Secondary malignancies, particularly solid tumors, are common in patients with chronic lymphocytic leukemia (CLL), but association of myeloproliferative neoplasms and chronic lymphocytic leukemia in the same patient is very rare. Case Outline We report of a 67-year-old man with B-cell chronic lymphoid leukemia (B-CLL) who developed primary myelofibrosis (PMF) nine years after initial diagnosis. Patient received alkylation agents and purine analogue, which can be a predisposing factor for the development of myeloproliferative neoplasms. JAK2V617F mutation was not present initially at the time of CLL diagnosis, but was found after nine years when PMF occurred, which indicates that B-CLL and PMF represent two separate clonal origin neoplasms. Conclusion Pathogenic mechanisms for the development of myeloproliferative and lymphoproliferative neoplasms in the same patient are unknown. Further research is needed to determine whether these malignancies originate from two different cell clones or arise from the same pluripotent hematopoietic stem cell.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "JAK2V617F mutacija kod bolesnika sa B ćelijskom hroničnom limfocitnom leukemijom i prefibrotičkom primarnom mijelofibrozom, JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis",
pages = "743-739",
number = "11-12",
volume = "143",
doi = "10.2298/SARH1512739R"
}
Ristić, S., Radojković, M., Kostić, T., Spasovski, V., Pavlović, S.,& Čemerikić-Martinović, V.. (2015). JAK2V617F mutacija kod bolesnika sa B ćelijskom hroničnom limfocitnom leukemijom i prefibrotičkom primarnom mijelofibrozom. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 143(11-12), 739-743.
https://doi.org/10.2298/SARH1512739R
Ristić S, Radojković M, Kostić T, Spasovski V, Pavlović S, Čemerikić-Martinović V. JAK2V617F mutacija kod bolesnika sa B ćelijskom hroničnom limfocitnom leukemijom i prefibrotičkom primarnom mijelofibrozom. in Srpski arhiv za celokupno lekarstvo. 2015;143(11-12):739-743.
doi:10.2298/SARH1512739R .
Ristić, Slobodan, Radojković, Milica, Kostić, Tatjana, Spasovski, Vesna, Pavlović, Sonja, Čemerikić-Martinović, Vesna, "JAK2V617F mutacija kod bolesnika sa B ćelijskom hroničnom limfocitnom leukemijom i prefibrotičkom primarnom mijelofibrozom" in Srpski arhiv za celokupno lekarstvo, 143, no. 11-12 (2015):739-743,
https://doi.org/10.2298/SARH1512739R . .
1
1

Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia

Radojković, Milica; Tošić, Nataša; Čolović, Nataša; Ristić, Slobodan; Pavlović, Sonja; Colović, Milica

(2012)

TY  - JOUR
AU  - Radojković, Milica
AU  - Tošić, Nataša
AU  - Čolović, Nataša
AU  - Ristić, Slobodan
AU  - Pavlović, Sonja
AU  - Colović, Milica
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/582
AB  - We report a case of de novo acute myeloid leukemia (AML) with unstable FLT3 gene mutations and stable NPM1 mutation. FLT3/D835 and NPM1 (Type A) mutations were detected upon diagnosis. During the relapse, the FLT3/D835 mutation changed to an FLT3/ITD mutation while the NPM1 (Type A) mutation was retained. Cytogenetic analyses showed the normal karyotype at diagnosis and relapse. Our findings raise interesting questions about the significance of these mutations in the leukemogenic process, about their stability during the evolution of the disease, and regarding the selection of appropriate molecular markers for the monitoring of minimal residual disease.
T2  - Annals of Clinical and Laboratory Science
T1  - Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia
EP  - 190
IS  - 2
SP  - 186
VL  - 42
UR  - https://hdl.handle.net/21.15107/rcub_imagine_582
ER  - 
@article{
author = "Radojković, Milica and Tošić, Nataša and Čolović, Nataša and Ristić, Slobodan and Pavlović, Sonja and Colović, Milica",
year = "2012",
abstract = "We report a case of de novo acute myeloid leukemia (AML) with unstable FLT3 gene mutations and stable NPM1 mutation. FLT3/D835 and NPM1 (Type A) mutations were detected upon diagnosis. During the relapse, the FLT3/D835 mutation changed to an FLT3/ITD mutation while the NPM1 (Type A) mutation was retained. Cytogenetic analyses showed the normal karyotype at diagnosis and relapse. Our findings raise interesting questions about the significance of these mutations in the leukemogenic process, about their stability during the evolution of the disease, and regarding the selection of appropriate molecular markers for the monitoring of minimal residual disease.",
journal = "Annals of Clinical and Laboratory Science",
title = "Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia",
pages = "190-186",
number = "2",
volume = "42",
url = "https://hdl.handle.net/21.15107/rcub_imagine_582"
}
Radojković, M., Tošić, N., Čolović, N., Ristić, S., Pavlović, S.,& Colović, M.. (2012). Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia. in Annals of Clinical and Laboratory Science, 42(2), 186-190.
https://hdl.handle.net/21.15107/rcub_imagine_582
Radojković M, Tošić N, Čolović N, Ristić S, Pavlović S, Colović M. Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia. in Annals of Clinical and Laboratory Science. 2012;42(2):186-190.
https://hdl.handle.net/21.15107/rcub_imagine_582 .
Radojković, Milica, Tošić, Nataša, Čolović, Nataša, Ristić, Slobodan, Pavlović, Sonja, Colović, Milica, "Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia" in Annals of Clinical and Laboratory Science, 42, no. 2 (2012):186-190,
https://hdl.handle.net/21.15107/rcub_imagine_582 .
2
3

Novel ORC4L Gene Mutation in B-Cell Lymphoproliferative Disorders

Radojković, Milica; Ristić, Slobodan; Divac Rankov, Aleksandra; Tomić, Branko; Arestorović, Aleksandra; Radojković, Dragica

(Lippincott Williams & Wilkins, Philadelphia, 2009)

TY  - JOUR
AU  - Radojković, Milica
AU  - Ristić, Slobodan
AU  - Divac Rankov, Aleksandra
AU  - Tomić, Branko
AU  - Arestorović, Aleksandra
AU  - Radojković, Dragica
PY  - 2009
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/380
AB  - B-cell lymphoproliferative disorders are characterized by marked genetic, morphological, and clinical heterogeneity. The identification of prognostic markers could help to develop risk-adapted treatment strategies. Because proliferation of cells is essential for tumor growth, analysis of the cell cycle might give additional information on tumor progression and clinical behavior. Because initiation of DNA replication represents a significant step in cell division, it is worthwhile to focus the attention to the origin recognition complex (ORC), protein complex essential for initiation of DNA replication. Studies have already shown that ORC-associated factors give a more accurate assessment of cell proliferation than previous markers for many types of malignancies, but so far there have been no studies of eventual role of ORC4L in B-cell lymphoproliferative disorders. Here, we describe 3 patients with B-cell lymphoproliferative disorders (2 with non-Hodgkin lymphoma and I with nonsecretory multiple myeloma) carrying a novel A286V mutation within ORC4L gene. All 3 patients were in the advanced stage of disease, but their response to the chemotherapy treatment was good and they achieved complete clinical remission in a relatively short period. Although the functional relevance of this mutation has not yet been elucidated, our observation raises a possibility that A286V mutation, which is constitutively present in these patients, might represent a favorable prognostic marker in B-cell lymphoproliferative disorders.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - American Journal of the Medical Sciences
T1  - Novel ORC4L Gene Mutation in B-Cell Lymphoproliferative Disorders
EP  - 529
IS  - 6
SP  - 527
VL  - 338
DO  - 10.1097/MAJ.0b013e3181b7f17c
ER  - 
@article{
author = "Radojković, Milica and Ristić, Slobodan and Divac Rankov, Aleksandra and Tomić, Branko and Arestorović, Aleksandra and Radojković, Dragica",
year = "2009",
abstract = "B-cell lymphoproliferative disorders are characterized by marked genetic, morphological, and clinical heterogeneity. The identification of prognostic markers could help to develop risk-adapted treatment strategies. Because proliferation of cells is essential for tumor growth, analysis of the cell cycle might give additional information on tumor progression and clinical behavior. Because initiation of DNA replication represents a significant step in cell division, it is worthwhile to focus the attention to the origin recognition complex (ORC), protein complex essential for initiation of DNA replication. Studies have already shown that ORC-associated factors give a more accurate assessment of cell proliferation than previous markers for many types of malignancies, but so far there have been no studies of eventual role of ORC4L in B-cell lymphoproliferative disorders. Here, we describe 3 patients with B-cell lymphoproliferative disorders (2 with non-Hodgkin lymphoma and I with nonsecretory multiple myeloma) carrying a novel A286V mutation within ORC4L gene. All 3 patients were in the advanced stage of disease, but their response to the chemotherapy treatment was good and they achieved complete clinical remission in a relatively short period. Although the functional relevance of this mutation has not yet been elucidated, our observation raises a possibility that A286V mutation, which is constitutively present in these patients, might represent a favorable prognostic marker in B-cell lymphoproliferative disorders.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "American Journal of the Medical Sciences",
title = "Novel ORC4L Gene Mutation in B-Cell Lymphoproliferative Disorders",
pages = "529-527",
number = "6",
volume = "338",
doi = "10.1097/MAJ.0b013e3181b7f17c"
}
Radojković, M., Ristić, S., Divac Rankov, A., Tomić, B., Arestorović, A.,& Radojković, D.. (2009). Novel ORC4L Gene Mutation in B-Cell Lymphoproliferative Disorders. in American Journal of the Medical Sciences
Lippincott Williams & Wilkins, Philadelphia., 338(6), 527-529.
https://doi.org/10.1097/MAJ.0b013e3181b7f17c
Radojković M, Ristić S, Divac Rankov A, Tomić B, Arestorović A, Radojković D. Novel ORC4L Gene Mutation in B-Cell Lymphoproliferative Disorders. in American Journal of the Medical Sciences. 2009;338(6):527-529.
doi:10.1097/MAJ.0b013e3181b7f17c .
Radojković, Milica, Ristić, Slobodan, Divac Rankov, Aleksandra, Tomić, Branko, Arestorović, Aleksandra, Radojković, Dragica, "Novel ORC4L Gene Mutation in B-Cell Lymphoproliferative Disorders" in American Journal of the Medical Sciences, 338, no. 6 (2009):527-529,
https://doi.org/10.1097/MAJ.0b013e3181b7f17c . .
17
11
14